Cancer drugs like cisplatin are designed to attack tumor cells, but new research shows these therapies can concentrate inside specialized molecular clusters within the nucleus, altering how ...

Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announces that it has entered into an agreement ...

Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announces that it has entered into an agreement with Cipla Limited and Cipla USA, Inc. to settle the ...

Dr. Alexandre Zlotta delivered the State-of-the-art lecture Who really needs surgery after neo-adjuvant chemotherapy? Dr.

A prospective, multicenter phase 2 trial evaluated the safety of neoadjuvant radiation plus immunotherapy before radical cystectomy for bladder cancer.

Virta Health, the leader in reversing metabolic disease, announced today results from a randomized, controlled Phase II clinical trial (RCT), offering an early signal that could reshape how advanced ...

KEYNOTE-B15 compared perioperative enfortumab vedotin plus pembrolizumab against neoadjuvant cisplatin-based chemotherapy in cisplatin-eligible MIBC, using event-free survival as the primary endpoint.

Long-term morbidity varies by chemotherapy regimen, with higher odds of worse renal impairment seen with EPx4 versus BEPx3.

Approximately 40% of patients with muscle-invasive bladder cancer achieve a clinical complete response after neoadjuvant ...

Cancers of the reproductive and urinary organs, known as genitourinary cancers, affect millions of people worldwide each year ...

The combination of tislelizumab and chemotherapy produced sustained and clinically meaningful survival benefits with manageable toxicity among patients ...

Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that the Tampa General Hospital (TGH) Cancer Institute is initiating a study evaluating the ...